Newsroom | 22899 results
Sorted by: Latest
-
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. “This is a seminal moment for Vir Biotechnology, marked by key high-potential partnerships on two of our programs showcasing the strength of our pipeline and technology platforms. Today, we announced a global strategic collaboration with Astellas and compelling new Phase 1 data for VIR-5500, demonstr...
-
AHF Secures Emergency Hearing to Challenge Florida's Planned Cuts to HIV Drug Program
TALLAHASSEE, Fla.--(BUSINESS WIRE)--An Administrative Law Judge today ordered an emergency hearing for Wednesday, February 25, in AIDS Healthcare Foundation's legal challenge to the Florida Department of Health's plan to slash eligibility for the state's AIDS Drug Assistance Program, known as ADAP. Beginning March 1, the Department plans to cut the qualifying income for the program from roughly $62,600 to $21,000 for an individual, dropping thousands of Floridians living with HIV from the cover...
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and we...
-
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approximately $113 million in net product revenue for ANKTIVA, representing an approximately 700% increase year-over-year. The Company also reported a 750% increase in unit sales volume and a 20% quarter-over-quarter increase in net product revenue, demonstrating sustained commercial momentum. In parallel...
-
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Evolves Human Health Operating Structure to Support Portfolio Execution...
-
Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026
PHILADELPHIA--(BUSINESS WIRE)--Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI), in Denver, CO, that a single intramuscular dose of VRON-0200, its novel, first-in-class, immunotherapy for HBV Functional Cure was able to “spark” and re-awaken durable HBV-specific immunity in the majority of chronically HBV-infe...
-
Covalon Honoured to Partner with the Association for Vascular Access and Global Expert Dr. Nancy Moureau to Tackle Critical IV Therapy Complications
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company focused on improving patient safety and clinical outcomes, today announced an upcoming Continuing Education webinar to be presented by internationally recognized vascular access expert Dr. Nancy Moureau and hosted by the distinguished Association for Vascular Access (AVA), a leading global authority on vascular access. The webinar will...
-
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at...
-
ECCO 2026 Data Validate Iterative Health’s Site Network Model for Faster, More Consistent Trial Execution
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Health announced the publication of scientific research at the 21st Congress of European Crohn’s and Colitis Organisation, Feb. 18–21, 2026....
-
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 at Increased Risk for Severe RSV Over Two RSV Seasons...